EMA Withdrawn: Biograstim (filgrastim) — AbZ-Pharma GmbH

View source ↗

Summary

Biograstim (filgrastim) by AbZ-Pharma GmbH has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Biograstim (filgrastim)

Snippet

Status: Withdrawn. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: AbZ-Pharma GmbH. Decision date: 23/09/2015